Home  »  Trendy Stocks   »  Inovio Pharmaceuticals Inc. (INO) stock rises in t...

Inovio Pharmaceuticals Inc. (INO) stock rises in the current market trading. Here’s to know why?

Inovio Pharmaceuticals Inc. (INO) stock surged by 1.26% at the last trading close as well as the INO stock price continued to rise by 5.00% in the current market session. INOVIO is a biotechnology company focusing on developing and commercializing precision-designed DNA drugs to cure and prevent infectious diseases, cancer, and HPV-related diseases. INOVIO is the first and only organization to show that a DNA drug can be administered directly into body cells using a patented smart interface, resulting in a powerful and tolerable immune response.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

What is happening?

INO announced that the findings of a study focusing on the human immune responses caused by INOVIO’s COVID-19 DNA vaccine candidate, INO-4800, against variants of concern have been released. INO-4800 induced a vigorous T cell response against all spike protein variants studied, which INO believes would be essential in providing defense against SARS-CoV-2 variants, as well as providing comparable levels of neutralizing action against both the UK and Brazilian variants as the original strain. INO-4800 is a DNA plasmid that is injected directly into body cells through a patented smart interface, resulting in a robust and tolerable immune response.

Clinical samples were taken from participants in INOVIO’s Phase 1 US-based INO-4800 clinical trial at various timepoints after vaccination. Antibodies with neutralizing action against the spike protein variants B.1.1.7 (UK variant), B.1.351 (South African variant), and P.1 were assessed (Brazilian variant). When compared to T cell responses to the initial Wuhan strain, the study found that T cell responses induced by INO-4800 vaccination were entirely preserved against the UK, South African, and Brazilian strains.

Furthermore,

Regarding INO-4800 development Dr. Kim said, INO intends to announce Phase 2 results in the second quarter of this year, and with FDA approval, they hope to step into Phase 3 in the second quarter of this year. The predicted safety profile of INO’s COVID vaccine, as well as its durability at room temperature for more than a year and possible ability to safely improve several times, places INOVIO’s COVID-19 vaccine as a critical component in combating the virus in both pandemic and infectious nations.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam